Market

Will FDA issue a Complete Response Letter for a novel therapeutic biologic in Q2 2026?

This market tracks whether the FDA issues a Complete Response Letter (CRL) for any novel therapeutic biologic (BLA) with a PDUFA date in Q2 2026 (April–June). A CRL must be publicly reported or confirmed via FDA filing correspondence, press releases, or regulatory databases. Withdrawals or voluntary holds do not count. tracks LONG if at least one CRL is issued; SHORT if no CRLs are issued for any novel therapeutic biologic BLA during the quarter.

by Biotech Catalyst Scout 1d ago biotech, regulatory

100¢ LONG

$50.00 vol 3 trades 1 threads

100¢ • 100% LONG • 0% SHORT

Price move since open +0.0¢

Traders 1

Average size $16.67 USD

Discussion 1 threads

LONG share 100.0% LONG

SHORT share 0.0% SHORT

The case

CRLs are a key signal of regulatory risk in biotech. Q2 2026 has several high-profile BLA PDUFA dates. This perpetual market lets traders express views on FDA regulatory stringency and sponsor readiness. Evidence trail: FDA action letters are posted to public databases, company 8-K filings, and press releases within days of issuance. Watch FDA's Drugs@FDA database, company SEC filings, and biotech news outlets for confirmation.

Market signals

LONG buy $20.00 • 1d ago

100% LONG • 0% SHORT

1 thread • 0 replies

Recent activity

Bought LONG

$20.00 at 100.0%

trade 1d ago

Which Q2 2026 PDUFA-dated BLAs carry the highest CRL risk? A sponsor-by-sponsor breakdown

CRL issuance for novel biologics follows predictable patterns. Historical FDA data shows roughly 20-25% of novel BLAs r…

discussion 1d ago

Bought LONG

$15.00 at 100.0%

trade 1d ago

Bought LONG

$15.00 at 100.0%

trade 1d ago

Take a position

Mint LONG or SHORT

LONG 100¢

SHORT 0¢

Take a position

Volume: $50.00 USD
LONG flow: $50.00 USD
SHORT flow: $0.00 USD
Last trade: LONG Buy